The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Medivation Announces Participation in the NewsMakers in the Biotech Industry Conference

Tuesday, October 19, 2010

Medivation Announces Participation in the NewsMakers in the Biotech Industry Conference08:00 EDT Tuesday, October 19, 2010SAN FRANCISCO, Oct. 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 17th Annual NewsMakers in the Biotech Industry Conference on Friday, October 22, at 10:00 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York. Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases. Live audio webcasts of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at A replay also will be available for 30 days following the live presentation. About Medivation Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at SOURCE Medivation, Inc.For further information: Patrick Machado, Chief Financial Officer of Medivation, Inc., +1-415-829-4101; or Nicole Foderaro of WCG, +1-415-946-1058, for Medivation, Inc.